Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obeldesivir in Participants From Birth to < 5 Years of Age With Respiratory Syncytial Virus (RSV) Infection
NCT06784973Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Mar 2025
- Primary completion
- Apr 2025
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of obeldesivir in respiratory syncytial virus infection (RSV), sponsored by Gilead Sciences. Started Mar 2025; status: terminated.
02
Drugs
obeldesivir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06784973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06784973.